Multi‑Mode Cognitive Processing Therapy for adults with PTSD
Efficacy of Multi-Modal Cognitive Processing Therapy for PTSD: A Longitudinal, Multicenter, Single-Blind RCT on Symptoms, Sleep, Anxiety, Depression, Remission, and Posttraumatic Growth
This program will try a multi‑mode form of Cognitive Processing Therapy to reduce PTSD symptoms and improve sleep and mood in adults aged 20–65 with PTSD.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 65 Years |
| Sex | All |
| Sponsor | Far Eastern Memorial Hospital Academic / other |
| Locations | 2 sites (New Taipei City, Banqiao District and 1 other locations) |
| Trial ID | NCT07105345 on ClinicalTrials.gov |
What this trial studies
This is a single‑blind, randomized, two‑arm longitudinal trial comparing Multi‑Mode Cognitive Processing Therapy (MMCPT) to treatment‑as‑usual (TAU) for patients with DSM‑5 PTSD. MMCPT follows the Resick CPT manual delivered as twelve weekly 90‑minute individual sessions by trained therapists, with rigorous monitoring of treatment fidelity and safety. Primary outcomes are clinician‑rated and self‑report PTSD severity (CAPS‑5 and PCL‑5); secondary outcomes include sleep measures (actigraphy, PSQI), anxiety (STAI), depression (HDRS‑17), remission rates, and posttraumatic growth (PTGI). Participants are assessed at baseline, mid‑treatment, post‑treatment, and at 3, 6, 9, and 12 months to capture short‑ and longer‑term effects.
Who should consider this trial
Good fit: Adults aged 20–65 with a DSM‑5 diagnosis of PTSD, a PCL‑5 score of 33 or higher, ability to consent, and a stable psychiatric medication regimen (if any) for at least 4 weeks are the intended participants.
Not a fit: People with psychotic disorders, bipolar I, current substance dependence, recent severe suicidal behavior, significant cognitive or neurological impairment, or those already in other psychological PTSD treatments are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, MMCPT could reduce PTSD symptoms and improve sleep, anxiety, depression, and long‑term recovery for adults with PTSD.
How similar studies have performed: Cognitive Processing Therapy is an evidence‑based treatment with many RCTs showing symptom reduction in PTSD, though this specific multi‑mode adaptation and its focused effects on sleep and long‑term outcomes are less established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged between 20 and 65 years * Diagnosed with PTSD according to DSM-5 criteria * Score ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5) * Able to provide informed consent * Stable psychiatric medication regimen (if any) for at least 4 weeks prior to enrollment Exclusion Criteria: * Diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder * Current substance dependence or abuse within the past 6 months * Severe suicidal ideation or suicide attempt in the past 6 months * Cognitive impairment or neurological disorder affecting participation * Concurrent participation in other psychological treatment for PTSD
Where this trial is running
New Taipei City, Banqiao District and 1 other locations
- Far Eastern Memorial Hospital — New Taipei City, Banqiao District, Taiwan (Not_yet_recruiting)
- Far Eastern Memorial Hospital — New Taipei City, Banqiao District, Taiwan (Recruiting)
Study contacts
- Study coordinator: Hsin-I Liu, PhD, RN
- Email: femh91095@femh.org.tw
- Phone: +886-2-8966-7000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.